Becton Dickinson (BDX) EVP Michael Feld reports small stock sale

Rhea-AI Filing Summary

Becton Dickinson & Co. executive Michael Feld, who serves as EVP, CRO and President of Life Sciences, reported a small stock sale. On 12/26/2025, he sold 74 shares of Becton Dickinson common stock at a price of $196.08 per share. After this transaction, he beneficially owned 16,506 shares directly.

The filing notes that this transaction was carried out under a Rule 10b5-1 trading plan that Feld adopted on February 7, 2025. Such plans allow insiders to pre-arrange trades according to set instructions, helping separate their personal trading activity from the timing of any nonpublic information they may hold.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Feld Michael

(Last) (First) (Middle)

C/O BECTON, DICKINSON AND COMPANY

1 BECTON DRIVE

(Street)

FRANKLIN LAKES NJ 07417

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BECTON DICKINSON & CO [ BDX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, CRO & Pres. Life Sciences

3. Date of Earliest Transaction (Month/Day/Year)
12/26/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/26/2025		S		74	D	$196.08	16,506	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

This reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 7, 2025.

	Donna Kalazdy, by power of attorney from Michael Feld	12/29/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Becton Dickinson (BDX) report for Michael Feld?

Becton Dickinson reported that executive Michael Feld sold 74 shares of common stock on 12/26/2025 at a price of $196.08 per share.

How many Becton Dickinson (BDX) shares does Michael Feld own after this transaction?

After the reported sale, Michael Feld beneficially owned 16,506 shares of Becton Dickinson common stock in direct ownership.

Was the Becton Dickinson (BDX) insider trade under a Rule 10b5-1 plan?

Yes. The filing states that the transaction was made under a Rule 10b5-1 plan adopted by Michael Feld on February 7, 2025.

What is Michael Feld’s role at Becton Dickinson (BDX)?

Michael Feld is identified as an officer of Becton Dickinson, with the title EVP, CRO & President, Life Sciences.

Is this Becton Dickinson (BDX) Form 4 filed by more than one reporting person?

No. The form indicates it is filed by one reporting person, reflecting transactions for Michael Feld only.

What type of security was involved in the Becton Dickinson (BDX) insider sale?

The transaction involved common stock of Becton Dickinson & Co., reported in Table I for non-derivative securities.